Xeris Biopharma Holdings Inc
NASDAQ:XERS
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.47
3.22
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Xeris Biopharma Holdings Inc
Xeris Biopharma Holdings Inc
Cash & Cash Equivalents
Xeris Biopharma Holdings Inc
Cash & Cash Equivalents Peer Comparison
JNJ
BMY
PFE
MRK
LLY
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Xeris Biopharma Holdings Inc
NASDAQ:XERS
|
Cash & Cash Equivalents
$57.6m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash & Cash Equivalents
$9.1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash & Cash Equivalents
$6.3B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
4%
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash & Cash Equivalents
$1.1B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-11%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash & Cash Equivalents
$11.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash & Cash Equivalents
$3.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-2%
|
See Also
What is Xeris Biopharma Holdings Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
57.6m
USD
Based on the financial report for Jun 30, 2024, Xeris Biopharma Holdings Inc's Cash & Cash Equivalents amounts to 57.6m USD.
What is Xeris Biopharma Holdings Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-3%
Over the last year, the Cash & Cash Equivalents growth was 25%. The average annual Cash & Cash Equivalents growth rates for Xeris Biopharma Holdings Inc have been -3% over the past three years , -3% over the past five years .
You don't have any saved screeners yet
